The arbs with least side effects market is projected to grow at a CAGR of 3.51%, in terms of value, from USD 7.87 Billion in 2020 to reach USD 10.34 Billion by 2028. This class of drug is used to block angiotensin II effects, and thus prevents the narrowing of blood vessels by angiotensin II action. The arbs with least side effects facilitates widening of blood vessels and reduce blood pressure in an individual. In general, arbs with least side effects are prescribed for patients with intolerance for angiotensin-converting-enzyme inhibitor.

The key factors contributing to the market growth includes increasing incidence of hypertension, chronic kidney diseases, kidney failure in diabetes, and heat failure, across the globe. For instance, according to American Heart Association statistics 2018, more than 103 million individuals in U.S.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1156



Some Key Factors Contributing to the Global Pharma & Healthcare Market Growth

Unprecedented revenue growth of the global pharma & healthcare industry is attributed to factors such as rising prevalence of chronic and acute diseases worldwide, increasing geriatric population, rising awareness of health & wellness among consumers, and growing demand for more advanced healthcare services. Increasing demand for advanced drugs and therapeutics, growing availability of next-generation diagnostics and treatment options – especially in developing countries like India and China – rise in R&D activities and clinical trials in the pharmaceutical and biotechnology sectors, increasing public and private investments in healthcare research projects, and rising consumer expenditure on healthcare are among the other significant factors contributing to the industry revenue growth.

Further key findings from the report suggest

  • arbs with least side effects market is rising at a growth rate of 4.4 percent in Asia Pacific followed by North America and Europe, with 3.4% and 3.2% CAGR respectively. Rising geriatric population in the region and rising obese population in the region will drive the demand for the market during forecast period across all regions.
  • Increasing incidence of hypertension & cardiovascular diseases in younger population are likely to contribute to the overall market growth.
  • Valsartan is the leading Angiotensin II Receptor Blocker in the market with market share of 20.8%. The Valsartan market was valued at USD 1.51 billion and is expected reach USD 1.97 billion by 2026. However, recalls of valsartan during 2018 and 2019, due to cancer concerns is a major challenge for the market growth of this market segment.
  • Azilsartan is expected to be the fastest growing market segment during forecast period 2019-2026 with a CAGR of 4.5%.
  • Asia Pacific is expected to witness a CAGR of 6.5 percent in the forecast period. Emerging markets such China and Japan are likely to witness high growth
  • The lack of well-established medical reimbursements for hypertension in various developing regions is likely to hinder the market growth

Top Players in the Global arbs with least side effects Market:

AstraZeneca, Daichii Sankyo, Novartis, Abbvie, Lupin, Novartis, Abbvie, Takeda, AstraZeneca, and Zydus Cadila.

The coronavirus pandemic has had a drastic impact on the global healthcare industry, with rising cases of COVID-19 worldwide, substantially growing hospital admission and readmission rates, and rising demand for telehealth and telemedicine services for remote patient monitoring. Furthermore, rising focus on development of rapid COVID-19 diagnostics such as the RT-PCR test kits, increased government funding for vaccine development, stringent regulatory norms and protocols for COVID-19 safety, and increasing sales of COVID-19 safety equipment, such as N-95 masks, face shields, PPE kits, and hand sanitizers, have driven the global pharma & healthcare industry revenue growth over the recent past.  

To know more about the report @ https://www.reportsanddata.com/report-detail/angiotensin-ii-receptor-blockers-market

arbs with least side effects Market Segmentation:

Type (Revenue, USD Million; 2018–2028)

  • Azilsartan
  • Candesartan
  • Eprosartan
  • Irbesartan
  • Losartan
  • Olmesartan
  • Telmisartan
  • Valsartan

Application (Revenue, USD Million; 2018–2028)

  • Hypertension
  • Cardiovascular risks
  • Kidney failure in diabetes
  • Chronic kidney diseases

Global arbs with least side effects Market Report: Regional Segmentation

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/1156

Read More Reports:

Hypertrophic Cardiomyopathy Therapeutics Market: https://www.reportsanddata.com/report-detail/hypertrophic-cardiomyopathy-therapeutics-market

Astaxanthin Market: https://www.reportsanddata.com/report-detail/astaxanthin-market

Wound Care Biologics Market: https://www.reportsanddata.com/report-detail/wound-care-biologics-market

Oligonucleotide Synthesis Market: https://www.reportsanddata.com/report-detail/global-oligonucleotide-synthesis-market

Influenza Diagnostics Market: https://www.reportsanddata.com/report-detail/influenza-diagnostics-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.